ArticleDiscover oncology2026
P53 loss and BRAF V600E mutation suggest potentially divergent pathways to aggressiveness in high grade differentiated thyroid carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-grade differentiated thyroid carcinoma (HGDTC) is a newly defined tumor entity in the 2022 WHO classification of thyroid tumors. Its diagnostic criteria, molecular characteristics, and clinical management system are still not fully developed, posing significant challenges for clinical diagnosis and treatment. CASE REPORT: Case 1 was a 75-year-old female who complained of intermittent cough for over a month. Color Doppler ultrasound of the neck indicated diffuse changes in the thyroid tissue, with nodules in the right lobe of the thyroid accompanied by coarse calcification. The mass was completely resected, and the postoperative pathology confirmed high-grade differentiated thyroid carcinoma. The microscopic manifestation was follicular carcinoma (30% in the solid area and 70% in the non-solid area). Immunohistochemical detection of P53 showed abnormal complete absence of expression in the solid area and non-solid area of the tumor cells. The patient was followed up for 5 months after surgery, and no tumor recurrence was observed. Case 2 was an 88-year-old female who complained of a mass in the anterior neck region for over 10 months, with intermittent rupture and bleeding for half a day. The mass was partially resected, and the postoperative pathology confirmed high-grade differentiated thyroid carcinoma. The microscopic manifestation was a mixture of the shoe-peg subtype (50%) and the classic subtype (50%). Immunohistochemical detection showed that the proliferation index in the hotspot area of Ki-67 was 20% in the shoe-peg subtype area and 10% in the classic subtype area. Molecular detection showed: BRAF V600E mutation. Follow-up for 3 months showed no disease progression.
conclusionThe P53 mutant immunophenotype may be an important immunological marker for the transformation of follicular thyroid carcinoma to high grade. The appearance of the shoe-peg morphology and increased Ki-67 proliferation index in the background of BRAF V600E mutation may be an important factor for the high-grade transformation of papillary carcinoma; The diagnosis of HGDTC should strictly follow the 2022 WHO standards, and an integrated diagnostic approach using histological morphology + immunohistochemistry + molecular detection can provide a basis for the diagnosis, prognosis assessment, and individualized treatment of HGDTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.